Exelixis to Webcast Fireside Chats as Part of Virtual Investor Conferences in May
Exelixis, Inc. (Nasdaq: EXEL) announced that CEO Michael M. Morrissey, Ph.D. will participate in three virtual investor conferences in May 2021. These include the 7th Annual Truist Securities Life Sciences Summit on May 4 at 3:30pm EDT, the BofA Securities 2021 Health Care Conference on May 11 at 2:00pm EDT, and the RBC Capital Markets 2021 Global Healthcare Conference on May 19 at 3:05pm EDT. Webcasts can be accessed via the company's website, and replays will be available for 14 days.
Exelixis focuses on developing new medicines for challenging cancers, with four commercial products available.
- None.
- None.
Exelixis, Inc. (Nasdaq: EXEL) today announced that Michael M. Morrissey, Ph.D., the company’s President and Chief Executive Officer, will participate in fireside chats at the following virtual investor conferences in May:
- 7th Annual Truist Securities Life Sciences Summit: Exelixis is scheduled to present at 3:30pm EDT / 12:30pm PDT on Tuesday, May 4, 2021.
- BofA Securities 2021 Health Care Conference: Exelixis is scheduled to present at 2:00pm EDT / 11:00am PDT on Tuesday, May 11, 2021.
- RBC Capital Markets 2021 Global Healthcare Conference: Exelixis is scheduled to present at 3:05pm EDT / 12:05pm PDT on Wednesday, May 19, 2021.
To access the webcast links, log onto www.exelixis.com and proceed to the News & Events / Event Calendar page under the Investors & Media heading. Please connect to the company’s website at least 15 minutes prior to the presentations to ensure adequate time for any software download that may be required to listen to the webcasts. Replays will also be available at the same location for 14 days.
About Exelixis
Founded in 1994, Exelixis, Inc. (Nasdaq: EXEL) is a commercially successful, oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Following early work in model system genetics, we established a broad drug discovery and development platform that has served as the foundation for our continued efforts to bring new cancer therapies to patients in need. Our discovery efforts have resulted in four commercially available products, CABOMETYX® (cabozantinib), COMETRIQ® (cabozantinib), COTELLIC® (cobimetinib) and MINNEBRO® (esaxerenone), and we have entered into partnerships with leading pharmaceutical companies to bring these important medicines to patients worldwide. Supported by revenues from our marketed products and collaborations, we are committed to prudently reinvesting in our business to maximize the potential of our pipeline. We are supplementing our existing therapeutic assets with targeted business development activities and internal drug discovery – all to deliver the next generation of Exelixis medicines and help patients recover stronger and live longer. Exelixis is a member of the Standard & Poor’s (S&P) MidCap 400 index, which measures the performance of profitable mid-sized companies. In November 2020, the company was named to Fortune’s 100 Fastest-Growing Companies list for the first time, ranking 17th overall and the third-highest biopharmaceutical company. For more information about Exelixis, please visit www.exelixis.com, follow @ExelixisInc on Twitter or like Exelixis, Inc. on Facebook.
Exelixis, the Exelixis logo, CABOMETYX, COMETRIQ and COTELLIC are registered U.S. trademarks. MINNEBRO is a registered Japanese trademark.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210427006099/en/
FAQ
What conferences will Exelixis participate in May 2021?
Who is the CEO of Exelixis?
What is Exelixis' stock symbol?
When is Exelixis' presentation at the Truist Securities Life Sciences Summit?
How can I access the webcasts for Exelixis' presentations?
